医学
糖尿病
葡萄糖稳态
疾病
2型糖尿病
内科学
胰高血糖素样肽-1
内分泌学
2型糖尿病
兴奋剂
受体
胰岛素抵抗
作者
Shiying Shao,Xiaoling Zhang,Qinqin Xu,Ruping Pan,Yong Chen
标识
DOI:10.1016/j.pharmthera.2022.108270
摘要
Currently, gastrointestinal hormone glucagon like peptide-1 (GLP-1) has received significant attention in maintaining glucose homeostasis through mechanisms involving augmentation of insulin, inhibition of glucagon secretion and regulation of gut motility. Therefore, GLP-1 receptor agonist (GLP-1RA) turns to be one of the most promising hypoglycemic agents for the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, the benefits of GLP-1 and GLP-1RAs are not limited to glucose control and weight loss. Here, we provide a concise overview of the roles of GLP-1 and GLP-1RAs in autoimmune disease, cardiovascular disease (CVD), diabetic kidney disease (DKD), diabetic foot ulcer (DFU), polycystic ovary syndrome (PCOS), and Alzheimer's disease (AD) as well as future challenges in this regard.
科研通智能强力驱动
Strongly Powered by AbleSci AI